WNK3 and ovarian cancer: Recently, it has been shown that treatment of ovarian cancer with the progesterone agonist or antagonist may induce similar adverse effects, including tumor promotion, due to the absence of classical nuclear PRs in ovarian cancer (Ponikwicka-Tyszko et al., 2019).